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Abstract
Background Generic drugs are considered therapeutically
equivalent to their original counterparts and lower in
acquisition costs. However, the overall impact of generic
substitution (GS) on global clinical and economic out-
comes has not been conclusively evaluated.
Objective To test whether (1) generics and original pro-
ducts yield the same health outcomes, and (2) generic ther-
apies save economic resources versus original therapies.
Methods We performed a systematic literature review in
Medline, Embase, and the Cochrane Database of System-
atic Reviews to identify original studies that examine
clinical or economic outcomes of GS. After standardized
data extraction, reported outcomes were categorized as
supporting or rejecting the hypotheses. Each reported
outcome was assessed and accounted for supporting and
opposing GS. One publication could provide multiple
outcome comparisons.
Results We included 40 studies across ten therapeutic
areas. Fourteen studies examined patients on de novo
therapy; 24 studies investigated maintenance drug therapy,
and two studies considered both settings. Overall, 119
outcome comparisons were examined. Of 97 clinical out-
come comparisons, 67 % reported no significant difference
between generic drugs and their off-patent counterparts. Of
22 economic comparisons, 64 % suggested that GS
increased costs. Consequently, hypothesis (1) was sup-
ported but hypothesis (2) was not. We found no major
differences among studies that investigated clinical out-
comes with de novo or maintenance therapy.
Conclusion The review suggests that clinical effects are
similar after GS. However, economic savings are not
guaranteed. More systematic research comparing clinical
and economic outcomes with or without GS is needed to
inform policy on the use of generic substitution.
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Key Points for Decision Makers
Studies that analyse the overall clinical and
economic consequences of generic substitution in
comparison to therapy with originator drugs are
lacking.
This review compares clinical outcomes (adherence,
adverse events, dose adjustments, concomitant
medication, etc.) and economic outcomes (drug
costs, outpatient and inpatient services costs,
copayments) with or without generic substitution as
reported in the literature to assess whether generic
substitution leads to the same clinical outcomes
while saving healthcare costs in general.
In 67 % of the reported outcome comparisons,
clinical effects were similar for generics and their
off-patent counterparts.
In 64 % of the reported outcomes, generic
substitution was associated with higher costs when
compared to therapy with their off-patent
counterparts.
Cost savings generated by generic substitution are
not guaranteed in the absence of robust research
specifically comparing one generic product to
another.
The present work includes very heterogeneous
studies on different drug types and should be
interpreted with caution.
1 Introduction
Governments and other healthcare payers are increasingly
challenged by rising healthcare expenditures and con-
strained resources. In countries from the Organization for
Economic Co-operation and Development, pharmaceutical
expenditures account on average for about 1.5 % of the
gross domestic product [1, 2]. Generic substitution (GS) is
a commonly employed method for reducing pharmaceuti-
cal costs by substituting patented original drugs through
generic counterparts with lower acquisition costs [3].
With the passage of the Drug Price Competition and
Patent Term Restoration Act (Hatch-Waxman Act) in the
USA in 1984, the market entry for generic drugs was
streamlined through an abbreviated approval process
requiring only a demonstration of bioequivalence for gen-
eric approval [4]. Although policies on GS vary from
country to country, the policies usually allow the authority
to substitute a cheaper generic equivalent for an off-patent
original product to a physician (prescribing by international
non-proprietary nomenclature) and/or a pharmacist (dis-
pensing of the product preferred by the policy maker or
payer).
Such policies are supported by a myriad of studies on
GS; most of them were published between the late 1970s
and the 1990s when generic substitution was a new and
challenging issue [5, 6]. Nevertheless, there is still a lack of
appropriate studies involving putatively similar generics—
with questionable differences of similarity—which might
partly explain the observable variance in clinical responses
and side effects. There are several reasons why GS may not
be appropriate which are not related to bioequivalence
issues [7–9]. For example, inappropriateness is determined
by excipient characteristics, but it may also depend on
disease entities and clinical conditions, for example, whe-
ther a generic drug is applied for de novo or for mainte-
nance therapy.
In order to be considered generic, a drug needs to match
the original product in dosage, safety, strength, adminis-
tration form, quality, performance and intended use. Under
these conditions, generics are generally considered to have
an equivalent clinical effect when substituted for the ori-
ginal name product [10, 11].
When two generic products are each at the far opposite
range of bioequivalence they are equivalent to a brand but
not to each other. This results in either over- or under-
dosing. Patient confusion and/or nurse confusion in drug
intake leads to decreased adherence. Decreased quality of
excipients and manufacturing quality can impact drug
release and intended action. Any of these scenarios can
lead to unintended adverse events that can cost more than
the savings in drug costs.
Although bioequivalent generic drugs exist for many
original products, it remains controversial whether bio-
equivalence reflects clinical equivalence. The safety of
substituting narrow therapeutic index drugs (NTI), for
instance, has been the topic of much debate. Since the
therapeutic window of these drugs is relatively small, they
can ‘‘exhibit limited or erratic absorption, formulation-
dependent bioavailability and intra-patient pharmacokinetic
variability that requires blood-level monitoring’’ [12]. Such
differences in clinical outcomes can also affect the intended
economic savings. If, for instance, rates for adverse events
were higher in patients switching to generic drugs, overall
expenses may be higher than expected or may even exceed
the amount spent previously for the original drug.
Considering the variety of drugs and drug types, litera-
ture pertaining to clinical and economic outcomes of GS
may be more robust in some therapeutic areas or treatment
stages than others. However, to date, we are not aware of
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any research that has attempted to summarize the entire
body of evidence on the impact of GS across multiple
therapeutic areas including clinical and economic
outcomes.
Therefore, the aim of this study was to evaluate whether
(1) original medications and their corresponding generic
equivalents yield the same health outcomes and (2) whe-
ther generic therapies save economic resources in contrast
to original therapies when evaluating health outcomes and
economic outcomes. A systematic review of the published
literature was conducted for patients starting a new therapy
(de novo) and patients on maintenance therapy.
2 Methods
2.1 Literature Search
A systematic literature search was performed in the fol-
lowing electronic databases: Medline using the PubMed
interface, the Cochrane Database of Systematic Reviews,
and Embase. A comprehensive search syntax (see
‘‘Appendix’’) that included the terms ‘‘generic substitu-
tion’’, ‘‘drug substitution’’, ‘‘drug switching’’, ‘‘adverse
event’’, ‘‘drug safety’’, ‘‘risk benefit ratio’’, ‘‘cost contain-
ment’’, ‘‘health economic’’, ‘‘adherence’’, ‘‘compliance’’,
‘‘persistence’’ and ‘‘medication adherence’’ was run
through PubMed and the Cochrane Database of Systematic
Reviews in September 2012. A subsequent literature search
was performed in November 2012 using a less distinct
syntax with the term ‘‘generic substitution’’ for titles and
abstracts in Medline, Cochrane Database of Systematic
Reviews and Embase. All searches were limited to the
publication years from 2000 to 2012. In addition, cited
references of the included studies were searched manually.
2.2 Literature Selection
We selected only full publications of original research
studies that focused on GS, examined clinical or economic
outcomes and included either a separate or pre-post com-
parator group. Exclusion criteria were: (a) publication
language was neither English nor German, (b) study design
implied no original research, (c) study endpoints did not
include clinical or economic outcomes, (d) study inter-
vention was not limited to generic switching but comprised
broader options such as therapeutic interchange. Addi-
tionally, studies were excluded that exclusively assessed
stakeholder opinions, satisfaction or knowledge of GS.
Likewise, budget impact analyses, which projected cost or
market consequences due to generic product entry to the
marketplace, were excluded. Both selection and data
extraction were realized by two independent scientists, who
were supplemented by a third scientist or discussion in
cases of disagreement.
2.3 Data Extraction
We developed a standardized assessment form, containing
the following domains: citation, funding source/conflict of
interest, research question/objective, specific drug, NTI
drug (yes/no), drug class, reference comparator, results,
outcome types, adherence measures, conclusions, study
type and limitations reported by the authors. For clinical
outcomes, we extracted reported endpoints on dose adjust-
ment, additional medication, adherence, adverse events,
healthcare utilization, surrogate outcome parameters, and
others. For economic outcomes, we extracted reported
endpoints on drug costs of the investigated drug as well as
additional drugs, outpatient and inpatient healthcare utili-
zation costs, co-payments and healthcare costs in general.
De novo and maintenance therapy regimens were
defined as whether or not patients had received the inves-
tigated active ingredient before study commencement.
Consequently, patients who were initiated on a chronic
treatment were classified as receiving de novo therapy.
2.4 Data Synthesis
We condensed the study data on each outcome by classi-
fying them as either supporting or opposing each of the two
hypotheses. According to the definition of generic drugs,
clinical outcomes were categorized as supporting the first
hypothesis if no statistically significant difference was
found between original and generic drug therapy or in case
clinical outcomes yielded statistically significant better
outcomes, e.g., lower adverse events or higher adherence
rates, than original drugs. The second hypothesis was
considered supported if the therapy costs under GS were
significantly reduced. Finally, each outcome comparison
was counted as supporting or not supporting and the per-
centage of supporting evidence of the total number of
comparisons was derived for each hypothesis.
As studies often examined several outcome measures,
the sum of outcome comparisons differs from the number
of studies included. Therefore, we distinguished between
terminology of ‘‘studies’’ and ‘‘outcome comparisons’’.
3 Results
3.1 Systematic Literature Search and Study
Characteristics
After removing duplicates, the systematic literature search
yielded 3,386 citations. After title and abstract screening,
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202 publications remained in the database. By means of full
text examination, 162 studies were excluded, most of them
(n = 68) for formal criteria, that is, the publication type
turned out to be a comment, editorial, letter to the editor or
an extended abstract. Forty-three studies were excluded
because they did not focus on economic, clinical, and/or
humanistic outcomes. Thirty-five publications were exclu-
ded due to study type (review, case-studies, hypothetical
cost-saving analyses). Ten studies were excluded because
they focused on therapeutic interchange rather than generic
substitution, and six articles were excluded because instead
of GS the main interventions were policy changes or price
adjustment measures. In the end, 40 studies (publications
[20–59] in the reference list) matched the selection criteria
and were included in the review (Fig. 1).
Included studies were performed in 16 countries from
three continents (20 studies from North America, eight
studies from Europe and 12 studies from Asia). While 80 %
of the studies investigated clinical outcomes only, 7.5 %
investigated economic outcomes only and 12.5 % examined
both clinical and economic outcomes. The studies covered
ten therapeutic classes, four of which included NTI drugs
(13 studies on NTI drugs of 40 included studies = 32 %).
The selected studies were largely heterogeneous regard-
ing therapeutic categories, types of therapy (i.e., chronic/
maintenance therapy vs. new/de novo therapy), study design,
switching sequences (e.g., parallel patient groups vs. cross-
over designs), settings, funding and others. (Tables 1, 2)
Study designs included randomized controlled trials
(17.5 %), prospective cohort studies (10 %) and retrospec-
tive cohort studies (60 %). Additionally, there was one
decision model, one non-randomized controlled trial (2.5 %
respectively) and three studies with study designs that
remained unclear (7.5 %). The time frame of the studies
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Fig. 1 PRISMA statement.
The flow diagram depicts the
flow of information through the
different phases (identification–
screening–eligibility—included)
of the systematic review. It
maps out the number of records
in each phase and shows how
many studies have been
included or excluded,
respectively
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ranged from eight weeks for interventional studies to
93 months in observational studies. Similarly, population
size ranged from eight patients to 221,881 patients (Table 1).
We identified 14 studies with a study population
receiving de novo therapy and 24 studies on maintenance
therapy. Two studies examined both de novo and
Table 1 Overview of studies included in the review
Study
no.






20. Alessi-Severini et al. [20] Antipsychotics M C 58
21. Amit et al. [21] Antiarrhythmics M C 114
22. Andermann et al. [22] AED M C 1,354
23. Araszkiewicz et al. [23] Antipsychotics D C 85
24. Assawawitoontip and
Wiwanitkit [24]
Antihypercholesterolemics (statins) D C 48
25. Boh et al. [25] Antihypercholesterolemics (statins) D C 138
26. Burkhardt et al. [26] AED M C 8
27. Carius and Schulze-Bonhage
[27]
AED M C 39
28. Chaluvadi et al. [28] AED M C 245
29. Diarra et al. [29] Immunosuppressives M C 59
30. Duh et al. [30] AED M E 1,142
31. Duh et al. [31] AED M C ? E 948
32. Fujii et al. [32] Oncology medication (folic acid) D C 42
33. Ghate et al. [33] Anticoagulants D C 37,756
34. Halkin et al. [34] Anticoagulants M C 975
35. Halkin et al. [35] Osteoporosis (bisphosphonates) D C 6,962
36. Haroldson et al. [36] Immunosuppressives M C ? E 30
37. Hartung et al. [37] AED M C 616
38. Helderman et al. [38] Immunosuppressives D C ? E 227
39. Jeong et al. [39] Anticoagulants M C 20
40. Kim et al. [40] Antihypercholesterolemics (statins) D C 211
41. Kluznik et al. [41] Antipsychotics M C 49
42. Labiner et al. [42] AED D ? M C 33,625
43. Lai et al. [43] Osteoporosis (bisphosphonates) D ? M C 131
44. Layton and Barbeau [44] Antipsychotics M E 100a
45. Lee et al. [45] Anticoagulants M C 35
46. LeLorier et al. [46] AED M E 671
47. LeLorier et al. [47] AED M C 671
48. McDevitt-Potter et al. [48] Immunosuppressives M C ? E 70
49. Milligan et al. [49] Anticoagulants M C 182
50. Momper et al. [50] Immunosuppressives M C 103
51. Narayanaswamy et al. [51] Glaucoma medication (prostaglandin
analogue)
D C 30
52. Pamugas et al. [52] Immunosuppressives D C 60
53. Ringe and Moller [53] Osteoporosis (bisphosphonates) D C 186
54. Sajbel et al. [54] Antipsychotics M C 17
55. Stro¨m and Landfeldt [55] Osteoporosis (bisphosphonates) D C 36,433
56. Ude et al. [56] Antihypertensives M C 221,881
57. Van Wijk et al. [57] Antihypertensives D C 1,028
58. Witt et al. [58] Anticoagulants M C ? E 2,299
59. Wiwanitkit et al. [59] Antihypercholesterolemics (statins) D C 43
D de novo therapy, M maintenance therapy, D ? M both, C clinical, E economic, C ? E clinical and economic, AED antiepileptic drug
a Patient number in the health economic decision model
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Table 2 Study characteristics
Characteristic De novo therapy Maintenance therapy Both
n = 14 studies n = 24 studies n = 2 studies
Outcome type
Clinical only 13 17 2
Economic only – 3 –
Clinical and economic 1 4 –
Country
USA 2 11 1
Canada – 6 –
Asia (Israel, Thailand, Japan, Taiwan, India, Philippines, Malaysia) 7 4 1
Europe (Germany, Austria, Netherlands, Poland, Slovenia, Sweden) 5 3 –
Funding
Industry (pharmaceutical and other) 6 12 1
Academia / healthcare organizations / public 1 4 –
No funding 2 – 1
Not stated 5 8 –
Therapeutic category
Antiepileptics – 9 1
Antiarrhythmics – 1 –
Anticoagulants 1 5 –
Antihypercholesterolemics 4 – –
Antihypertensives 1 1 –
Antipsychotics 1 4 –
Ocular (glaucoma) 1 – –
Immunosuppressives 2 4 –
Oncology 1 – –
Osteoporosis 3 – 1
Narrow therapeutic index (NTI) 2 10 1
Study design
Interventional studies 5 4 –
RCT, cross-over (brand to generic and v.v.) 3 2 –
RCT, parallel groups, no switch (brand only vs. generic only) 2 – –
Controlled trial, non-randomized – 1 –
Simple substitution (brand to generic) – 1 –
Observational studies, prospective 1 2 1
Parallel groups, no switch (brand only vs. generic only) 1 – –
Simple substitution (brand to generic) – 2 –
Simple substitution (brand to generic vs. brand or generic only) – – 1
Observational studies, retrospective 7 16 1
Parallel groups, no switch (brand only vs. generic only) 3 1 –
Simple substitution (brand to generic, incl. switch-back if appl.) – 12 –
Simple substitution (brand to generic vs. brand or generic only) 3 – –
Cross-over (brand to generic and v.v.) – 1 –
Open cohort (all possible switches) 1 2 1
Decision analytic model – 1 –
Simple substitution (brand to generic vs. brand or generic only) – 1 –
Unclear 1 2 –
Simple substitution (brand to generic) – 2 –
Parallel groups, no switch (brand only vs. generic only) 1 – –
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maintenance therapy under generic substitution. Study
characteristics grouped by de novo or maintenance therapy
remained heterogeneous. However, studies on economic
outcomes seemed to examine maintenance therapy more
often (seven of eight economic outcomes comparison
studies) than de novo therapy (one of eight studies). In
addition, GS of NTI drugs was examined more often in
maintenance therapy (10 of 12 NTI studies), than in de
novo therapy (2 of 12 NTI studies). Accordingly, mainte-
nance therapy studies covered more sensitive therapeutic
categories than studies on de novo therapy. While studies
on maintenance therapy included mostly antiepileptic
drugs (AEDs), anticoagulants, antipsychotic drugs and
immunosuppressive drugs, studies on de novo therapy
included mainly antihypercholesterolaemic drugs or oste-
oporosis medication and others.
3.2 Clinical Outcomes
Clinical outcomes were examined by 37 of 40 studies that
led to 97 comparisons of clinical outcomes. These studies
covered all ten therapeutic classes as described above and
investigated about 26 different drugs. Table 3 displays an
overview of our findings sorted by de novo and mainte-
nance therapy.
Of the investigated clinical outcome comparisons in de
novo therapy, 76 % found generic drugs to produce similar
clinical outcomes when compared with the original refer-
ence drugs (25 of 33 clinical outcome comparisons).
Likewise, 64 % of the examined clinical outcome com-
parisons demonstrated equal effectiveness with GS (38 of
59 clinical outcome comparisons) in maintenance therapy
patients. Of the studies that included both therapy types
(treatment stages), 40 % reported similar clinical outcomes
with generic substitution.
All in all, 67 % of the clinical outcome comparisons
included in this analysis revealed no difference between
original and generic drug therapy effectiveness with gen-
eric therapy, and therefore, supported our first hypothesis.
3.3 Economic Outcomes
Regarding economic outcomes, we extracted reported data
on drug costs for the investigated drug and/or potential co-
medication, as well as costs on healthcare utilization
(inpatient and outpatient) and co-payments.
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3 – 3 4 – 1 11
[32, 34, 55] [21, 26, 37] [22, 31, 47, 56] [42]
Adherence 1 3 3 – 1 – 8
[57] [34, 53, 55] [39, 45, 46] [43]
Adverse
events
8 3 11 3 1 – 26
[23–25, 32, 40,
51, 52, 59]
[33, 38, 53] [20, 21, 29, 36, 39,
45, 48–50, 54, 58]
[27, 28, 41] [43]
Healthcare
utilization
4 – 5 2 – 1 12
[23, 34, 38, 57] [20, 21, 35–37] [31, 47] [42]
Surrogate
endpoints
6 2 9 5 – – 22
[24, 25, 32, 40,
52, 59]
[51, 53] [20, 29, 36, 39, 45,
48, 49, 54, 58]
[26, 27, 35, 41,
50]




25 8 38 21 2 3 97
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Of the 40 included studies, three examined economic
outcomes only whereas another five studies examined both
economic and clinical outcomes. These eight studies led to
22 outcome comparisons. The most frequent study design
underlying the economic analyses was retrospective data-
base analysis (five of eight economic studies). Another
study projected actual economic observations from a
Canadian retrospective open cohort study to a US setting
using mathematical approaches, while another study
determined the relapse incidence at which switching to a
generic drug was cost-neutral through a simple decision
analytical model. Only one prospective cohort study was
found within this economic context.
These eight studies examined economic outcomes of GS
in epilepsy patients treated with AEDs (37.5 %), organ
transplant recipients treated with immunosuppressives
(37.5 %), atypical neuroleptics (12.5 %) and anticoagu-
lants in patients with continuous use of warfarin (12.5 %).
Seven of eight economic studies (87.5 %) found drug
acquisition costs of the investigated medication to be
lower for generic drugs (Table 4). Five studies identified
drug costs for additional medication during generic drug
use. In four of them (80 %) the supplementary medication
costs exceeded the cost savings obtained from lower costs
for the investigated medication due to GS. Total costs for
inpatient and outpatient healthcare utilization (e.g., phy-
sician visits, hospitalization visits, etc.) were always lower
with use of original products. Only costs that arose during
the study periods ranging from 180 days to 5 years were
included.
In the consolidated evaluation of economic outcome
comparisons, 64 % indicated that staying with an original
product incurs lower costs than GS. One of these studies
examined economic outcomes for de novo therapy, in this
case immunosuppressives after organ transplantation, and
found total costs to be lower with originator therapy. In the
group of maintenance therapy, 55 % of the economic
comparisons opposed our second hypothesis.
Seven of eight economic studies calculated the total
healthcare costs according to their reported economic
outcomes. Contrary to our finding from counting whether
or not outcome comparisons supported our second
hypothesis, half of these studies found that GS leads to
lower costs.
4 Discussion
Our findings suggest that 67 % of the evidence reported
clinical similarity of GS as compared to original drug
therapy, whereas 64 % of the comparisons of economic
outcomes suggest costs to be lower when using original
drugs. Accordingly, our first hypothesis was supported and
our second hypothesis was rejected.
When stratifying the groups by de novo and mainte-
nance therapy, we found a slight difference among studies
on clinical outcomes: 76 % of clinical comparisons found
similar effects for generics in de novo therapy and 64 % of
clinical comparisons found similar effects in generics in
maintenance therapy. Likewise, all economic comparisons
in patients receiving de novo therapy (one study) versus
56 % in maintenance therapy (seven studies) revealed
lower cost with originator therapy. None of the economic
outcome comparisons revealed similar costs. However, the
Table 4 Economic outcome comparisons (study references in square brackets)
Economic outcomes De novo patients starting on generics Maintenance patients switching to generics Total
n = 8









Drug costs of investigated
drug
– 1 7 – 8
[38] [30, 31, 36, 44, 46, 48,
58]
Drug costs of concomitant
medication
– 1 – 4 5
[38] [30, 31, 46, 58]
Outpatient services costs – 1 – 3 4
[38] [31, 46, 58]
Inpatient services costs – 1 – 3 4
[38] [31, 44, 46]




– 4 8 10 22
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low number of studies in each group limits the generaliz-
ability of these results.
The majority of economic studies are related to sensitive
therapeutic categories and maintenance therapy. Data
on economic consequences of generic drug substitution
in less sensitive therapeutic categories such as anti-
hypercholesterolemics or osteoporosis were missing or did
not meet our inclusion criteria. Thus, our review may suffer
from publication bias and the economic conclusions are
only relevant to these sensitive therapeutic areas. In the
absence of evidence, no conclusions on economic advan-
tages of one policy (e.g., generic substitution) over the other
(e.g., originator therapy) can be drawn for less sensitive
therapeutic areas. Moreover, with only one economic study
analysing the economic impact of generic substitution for
de novo therapy, the result must not be generalized. Hence,
more evidence is needed to examine the economic impact of
generic substitution in a real-life therapy situation, where
chronic generic therapy may involve multiple substitution
and thus multiple switching. Total healthcare costs were
calculated in seven of eight studies. Half of these found cost
reductions to be realized with generic drugs, whereas the
other half found costs to be lower with the original drug. In
contrast, our dichotomous classification supporting or
opposing GS resulted in a stronger preference for originator
drugs (lower healthcare cost in general).
The high heterogeneity among the cost types reported in
the economic studies is also important to note, even among
those which claimed to take the payer perspective. If only
drug costs of the investigated drug and concomitant med-
ication were examined, findings were likely to show cost
reductions after GS. However, if dose adjustments, co-
medication or healthcare utilization were considered
depending on the rates of adverse events, GS no longer
realized cost reductions. Instead, economic outcomes
became more preferable in original drugs. It may be
speculated that such results depend on additional factors
such as therapeutic area, patient age or education level,
number of medications or general healthcare context.
These considerations also apply to our analysis on
clinical outcomes. If we focus on patient-relevant outcomes
such as additional medication, adherence and adverse
events only, disregarding surrogate outcomes or others,
67 % (12 out of 18 clinical outcome parameters for these
three dimensions) of the categorized data on clinical out-
comes remain in favour of our hypothesis of similar clin-
ical effects. Evidence on all clinical outcomes did support
the first hypothesis more often in de novo therapy (76 % of
the relevant 33 clinical outcome comparisons) than in
maintenance therapy (64 % of the relevant 59 clinical
outcome comparisons).
This review has multiple limitations which should be
considered when interpreting the results. We used a
dichotomous classification of evidence, whether studies
reported a statistically significant difference between gen-
eric and original drugs or not. We used this simplifying
approach as the broad topic of this review resulted in a very
heterogeneous pool of studies which impaired compara-
bility and information had to be condensed in order to be
able to provide a meaningful summary on the topic.
Moreover, studies were not critically appraised regarding
methodological aspects in a formal manner. For example, a
comparison of therapy with one generic drug versus ther-
apy with the originator drug in an 8-week randomized
clinical study may answer a different question to a 2-year
observational study in a real-life setting including multiple
switching under a generic substitution policy. Among the
included studies, three compared original drugs with their
generic counterpart as well as drugs of different active
ingredients [13–15]. Of these only the data comparing
generics with the original reference drug were included.
Additionally, our analysis did not include substitution
between biological originator drugs and biosimilars.
Finally, we took a semi-quantitative approach to summa-
rize the evidence. Rather than pooling results in a formal
meta-analysis, we simply counted outcome comparisons in
favour of or against the compared strategies, and therefore
did not weigh studies by sample size or precision. We also
ignored dependency between multiple comparisons within
one study and did not perform formal statistical tests or
uncertainty analysis. Therefore, our analyses are merely
exploratory, and should be interpreted with appropriate
caution.
Of the included studies, 22 displayed a direct financial
interest in their investigated drugs. In 55 % of these stud-
ies, the potential interest was linked to the original product,
in 31 % of the studies this was linked to a generic and three
studies (14 %) could not be specified, for instance due to a
variety of author honoraria from several industry partners.
Among those with a link to an original product, ten of
twelve studies (83 %) found original drugs to generate
preferable outcomes (clinical or economic), and of the
studies with a link to a generic product, six of seven studies
(86 %) found generics to be the dominant drug. Therefore,
detection bias should be further explored in subsequent
analyses.
We found economic outcomes to be more favourable in
original drugs than in generics, which is in accordance with
Duh et al. [16] who detected higher than expected health-
care costs in generic AEDs and revealed that GS may even
increase healthcare costs. The included studies of this
review mainly suggested further underpinnings of their
specific findings, or extensions of the covered methodology
such as reporting of additional outcomes, broader or dif-
ferent populations or different medications. Considering
the variety of original research that we identified with our
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systematic literature search, few systematic reviews or
meta-analyses have been published focusing only on spe-
cific aspects of GS, mainly within sensitive therapeutic
classes [16–19]. Kesselheim et al. [18], for instance,
investigated the impact of generic AEDs on clinical out-
comes, namely seizure control, and hypothesized superi-
ority of original products. Although the meta-analysis
showed ‘‘no difference in the odds of uncontrolled seizure
for patients on generic medications compared with patients
on original-name medications’’, observational studies
found health services utilization to be slightly increased
after GS. The authors attributed this insight to a detection
bias caused by ‘‘concern from patients or physicians about
the effectiveness of generic AEDs’’. Similarly, economic
outcomes of AEDs were assessed by Duh et al. [16] who
found generic AEDs to cause higher healthcare costs than
their original counterparts in both stable and unstable epi-
lepsy patients. Multiple-generic substitution increased this
effect even more.[ The findings of these two reviews apply
to our results in regard to both clinical and economic
outcomes. Desmarais et al. [17] investigated the clinical
equivalence of original and generic psychotropic medica-
tions such as anticonvulsants and mood stabilizers. Besides
raising compliance issues, generics caused clinical deteri-
oration, adverse effects and changes in pharmacokinetics
while leading to lower than expected cost savings. The
authors therefore suggested generic switching of psycho-
tropic medication to be advised only on an individual basis
while simultaneously monitoring the switch [17].
Another systematic review by Kesselheim et al. [18]
focused on clinical evidence in cardiovascular disease
while also examining related opinions of editorialists. The
analyses did not reveal superiority of either drug type, but
found a considerable amount of editorials opposing generic
drugs. While these reviews addressed mostly sensitive
therapeutic categories, most of them found generics to
result in similar clinical effects. In accordance with our
findings, these reviews found economic consequences to be
higher in periods of generic use compared to periods of
original use. Altogether, these reviews revealed reserva-
tions and concerns in treatment routines of generics.
Based on our findings, we are able to observe suggested
trends based on a significantly heterogeneous review.
Future work will look to validate these trends with more
robust methods as demonstrated in other more homogenous
clinical and economic reviews.
We detected a need for more systematic reviews that
determine the impact of GS on clinical and economic
outcomes while differentiating between therapeutic classes
since substitution may be more sensitive in some areas than
others due to their pharmaceutical characteristics. More-
over, patient groups should be subdivided into patients
receiving a new and those receiving a maintenance therapy
as generics may have different effects for those who start a
new treatment than for those who are already stable on a
treatment. This is especially true for sensitive therapeutic
classes not only with a narrow therapeutic window (e.g.,
AEDs), but also others such as drugs used in schizophrenia.
5 Conclusion
Despite mainly similar clinical effects, our analyses sug-
gest that original to generic drug substitution may not
reduce costs, particularly in sensitive therapeutic areas such
as with AEDs or immunosuppressive drugs. Evidence on
clinical outcomes was slightly more distinct in studies with
patients on maintenance therapy than in treatment-naı¨ve
patients. As we found only one economic study in patients
receiving de novo therapy, a comparison with the
remaining seven studies with maintenance therapy patients
seems unreasonable. Since evidence is heterogeneous and
in this context influenced by several other influencing
factors, further research is needed in GS. Studies should
ideally be based on real world evidence to determine the
true comparative effectiveness of GS. Preference should be
given to interventional approaches which randomize
patients to generic and brand arms, control for co-mor-
bidities, disease severity, maintenance versus de novo
therapy, etc. We therefore recommend that research in GS
focuses on systematic approaches in therapeutic areas in
order to analyse outcomes and uncertainty.
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Appendix: search strategy
Detailed search syntax for Medline via PubMed
and the Cochrane Database of Systematic Reviews
Search Query
1 ‘‘Drug substitution’’ [mesh]
2 ‘‘Drugs, generic’’ [mesh]
3 ‘‘Drug substitutions’’ or ‘‘substitutions, drug’’ or ‘‘drug
switching’’ or ‘‘switching, drug’’ or ‘‘therapeutic
substitution’’ or ‘‘generic substitution’’ or ‘‘generic
substitutions’’ or ‘‘generic drug’’
4 ‘‘Generic medicine’’ or ‘‘generic product’’ or originator or
‘‘branded generic’’ or ‘‘mature products’’
5 1 or 2 or 3 or 4
6 ‘‘Drug toxicity’’ [mesh]
7 ‘‘Adverse event’’ or ‘‘adverse events’’ or ‘‘adverse effect’’ or
‘‘treatment failure’’ or ‘‘drug safety’’ or ‘‘drug interaction’’
or ‘‘patient safety’’ or ‘‘clinical response’’ or ‘‘side effects’’
or ‘‘risk-benefit balance’’ or ‘‘risk benefit balance’’ or
‘‘risk-benefit ratio’’ or ‘‘risk benefit ratio’’ or ‘‘adverse
outcomes’’
8 ‘‘Cost containment’’ or ‘‘cost saving’’ or ‘‘cost savings’’ or
‘‘cost minimization’’ or ‘‘health economic’’ or ‘‘resource
use’’ or ‘‘resource utilization’’
9 Adherence or compliance or persistence or ‘‘medication
adherence’’
10 6 or 7 or 8 or 9
11 5 and 10 limits: (language: eng, ger; published: after 2000)
The query in Medline via Pubmed resulted in 3,030 hits
The query in the Cochrane Database of Systematic Reviews
resulted in 28 hits
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